3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
110
Carcinoma, Non-Small-Cell Lung
63
Lung Neoplasms
27
Hodgkin Disease
14
Lymphoma
10
Neoplasm Metastasis
9
Triple Negative Breast Neoplasms
8
Neoplasms
8
Recurrence
7
Prostatic Neoplasms
7
Small Cell Lung Carcinoma
5
Sarcoma
5
Rhabdomyosarcoma
5
Lymphoma, Large B-Cell, Diffuse
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
4
Breast Neoplasms, Male
4
Brain Neoplasms
4
Adenocarcinoma of Lung
4
Ovarian Neoplasms
3
NSCLC
3
Mesothelioma, Malignant
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Esophageal Squamous Cell Carcinoma
3
Interventions
apatinib
2
Erlotinib Hydrochloride
2
Carboplatin
2
sintilimab
1
durvalumab
1
camrelizumab
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
Telescopes
1
Radiotherapy
1
Radiosurgery
1
Pemetrexed
1
Gemcitabine
1
Gefitinib
1
Etoposide
1
Docetaxel
1
Dasatinib
1
Cisplatin
1
Afatinib
1
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Respiratory Tract Diseases
×
Vinorelbine
×
Clear all
NCT03402048
2020-11-04
EPIC
University of Turin, Italy
Phase 3
Unknown
567 enrolled